Apellis Pharmaceuticals Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Apellis Pharmaceuticals de 62.7% y 25.6% por año respectivamente. Se prevé que el BPA crezca en un 61.8% al año. Se espera que la rentabilidad financiera sea de 37.8% en 3 años.

Información clave

62.8%

Tasa de crecimiento de los beneficios

61.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.1%
Tasa de crecimiento de los ingresos	25.1%
Rentabilidad financiera futura	37.8%
Cobertura de analistas	Good
Última actualización	28 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Recent updates

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14

Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates

Nov 09

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:APLS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,654	385	413	305	14
12/31/2025	1,193	101	206	178	15
12/31/2024	821	-129	-163	-122	17
3/31/2024	524	-417	-551	-550	N/A
12/31/2023	397	-529	-596	-595	N/A
9/30/2023	273	-606	-639	-638	N/A
6/30/2023	185	-657	-625	-623	N/A
3/31/2023	106	-691	-582	-580	N/A
12/31/2022	75	-652	-515	-514	N/A
9/30/2022	113	-634	-486	-485	N/A
6/30/2022	97	-638	-501	-500	N/A
3/31/2022	81	-702	-522	-521	N/A
12/31/2021	67	-746	-564	-563	N/A
9/30/2021	256	-520	-310	-309	N/A
6/30/2021	251	-460	-245	-240	N/A
3/31/2021	251	-360	-211	-205	N/A
12/31/2020	251	-345	-166	-160	N/A
9/30/2020	1	-536	-389	-385	N/A
6/30/2020	N/A	-470	-340	-338	N/A
3/31/2020	N/A	-423	-285	-284	N/A
12/31/2019	N/A	-305	-213	-211	N/A
9/30/2019	N/A	-228	-175	-174	N/A
6/30/2019	N/A	-194	-154	-153	N/A
3/31/2019	N/A	-156	-145	-144	N/A
12/31/2018	N/A	-128	-131	-131	N/A
9/30/2018	N/A	-109	-102	-102	N/A
6/30/2018	N/A	-85	-80	-80	N/A
3/31/2018	N/A	-64	-61	-61	N/A
12/31/2017	N/A	-51	N/A	-47	N/A
9/30/2017	N/A	-39	N/A	-38	N/A
6/30/2017	N/A	-35	N/A	-33	N/A
3/31/2017	N/A	-30	N/A	-28	N/A
12/31/2016	N/A	-27	N/A	-26	N/A
9/30/2016	N/A	-29	N/A	-27	N/A
6/30/2016	N/A	-53	N/A	-24	N/A
3/31/2016	N/A	-50	N/A	-21	N/A
12/31/2015	N/A	-47	N/A	-19	N/A
9/30/2015	N/A	-41	N/A	-14	N/A
6/30/2015	N/A	-12	N/A	-14	N/A
3/31/2015	N/A	-12	N/A	-12	N/A
12/31/2014	N/A	-11	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que APLS sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que APLS sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que APLS sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (25.6% al año) de APLS crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (25.6% al año) de APLS crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de APLS sea alta dentro de 3 años (37.8%)

Apellis Pharmaceuticals Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Consensus EPS estimates fall by 18%

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Consensus EPS estimates fall by 13%, revenue upgraded

Recent updates

Independent Director notifies of intention to sell stock

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 18%

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold US$525k worth of stock

Price target increased by 9.0% to US$71.44

Price target decreased by 9.6% to US$66.69

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

CFO & Treasurer exercised options and sold US$633k worth of stock

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Price target decreased by 9.8% to US$93.23

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

New minor risk - Share price stability

General Counsel notifies of intention to sell stock

Chief People Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Consensus revenue estimates increase by 57%, EPS downgraded

Price target increased by 12% to US$100

Chief Commercial Officer notifies of intention to sell stock

Insufficient new directors

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Chief Commercial Officer notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Co-Founder exercised options to buy US$6.5m worth of stock.

Co-Founder & Director exercised options and sold US$62k worth of stock

Price target increased by 13% to US$85.06

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Co-Founder notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer